FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2326249637> ?p ?o ?g. }

• W2326249637 abstract "Background: Breast cancer prevention is now possible using anti-estrogen drugs such as tamoxifen and raloxifene. However, the anti-estrogen drugs do not prevent all types of breast cancer. These drugs are useful for the prevention of estrogen receptor (ER)-positive breast cancers, but are unable to prevent the development of ER-negative breast cancer. ER-negative breast cancers are highly aggressive and are particularly difficult to treat. Thus, there is an urgent need to develop ways to prevent these life-threatening cancers. Using a transgenic mouse model of ER-negative breast cancer, our laboratory has previously demonstrated that LGD100268, a ligand to the RXR nuclear hormone receptor, prevents up to 90% of the ER-negative breast cancers in these mice. However, because this drug does not prevent all breast cancers in these mice, we have attempted to achieve more effective cancer prevention by combining two cancer preventive drugs. We hypothesized that the combination of the rexinoid LG100268 in combination with tamoxifen will more effectively prevent the development of ER-negative breast cancer. To test this hypothesis, we used the p53-null mouse model that develops both ER-positive and ER-negative mammary tumors to determine whether the combination of a rexinoid and an anti-estrogen is more effective than either treatment alone in preventing ER-positive and ERnegative mammary tumors. Methods: Using our standard transplant protocol, p53-null Balb/C donor mice was transplanted into both cleared inguinal mammary fat pads of Balb/C p53 wild-type mice. Mice were separated into 5 treatment groups (15 mice each). 1) Sham Control: 2) Vehicle Control: 3) Tamoxifen + Vehicle: 4) Sham pellet (5mg) + Rexinoid: (at 50mg/kg), 5) Tamoxifen + Rexinoid: Mice were treated for 60 days with each drug sequentially. Mice were observed daily for tumor formation and the percentage of tumor free mice were recorded. Tumor incidence and time to tumor formation was analyzed. The expression of mammary tissue biomarkers was done using immunohistochemistry and real time QRT-PCR. Results: 38% of sham and 41% vehicle control animals developed tumors. Sequential treatment with tamoxifen and LGD100268 prevented more (8% incidence) than tamoxifen (24% incidence) or LGD100268 (20% incidence) alone. Proliferation markers Ki67 and cyclin D1 were markedly reduced in the mammary tissue from the mice treated with the combination therapy. We have also observed induction of rexinoid target genes ABCA1 and ABCG1, in the retinoid group and in the combination group. Conclusions: The combination treatment of rexinoid LG100268 and tamoxifen is more effective at preventing mammary tumors than either agent alone. Based on these studies, clinical trials using the combination of tamoxifen and rexinoids should be considered for the prevention of breast cancer in high-risk patients. Supported by NIH grants P50 CA58183 (PB, DM) and R01 CA101211 (PB, DM). Citation Information: Cancer Prev Res 2010;3(12 Suppl):B56." @default.
• W2326249637 created "2016-06-24" @default.
• W2326249637 creator A5023874610 @default.
• W2326249637 creator A5029537735 @default.
• W2326249637 creator A5043733113 @default.
• W2326249637 creator A5064622016 @default.
• W2326249637 creator A5069756775 @default.
• W2326249637 creator A5081500324 @default.
• W2326249637 creator A5086922933 @default.
• W2326249637 date "2010-12-01" @default.
• W2326249637 modified "2023-09-27" @default.
• W2326249637 title "Abstract B56: Rexinoid LG100268 and tamoxifen prevents mammary tumors in p53-null mammary gland mice" @default.
• W2326249637 doi "https://doi.org/10.1158/1940-6207.prev-10-b56" @default.
• W2326249637 hasPublicationYear "2010" @default.
• W2326249637 type Work @default.
• W2326249637 sameAs 2326249637 @default.
• W2326249637 citedByCount "0" @default.
• W2326249637 crossrefType "proceedings-article" @default.
• W2326249637 hasAuthorship W2326249637A5023874610 @default.
• W2326249637 hasAuthorship W2326249637A5029537735 @default.
• W2326249637 hasAuthorship W2326249637A5043733113 @default.
• W2326249637 hasAuthorship W2326249637A5064622016 @default.
• W2326249637 hasAuthorship W2326249637A5069756775 @default.
• W2326249637 hasAuthorship W2326249637A5081500324 @default.
• W2326249637 hasAuthorship W2326249637A5086922933 @default.
• W2326249637 hasConcept C121608353 @default.
• W2326249637 hasConcept C126322002 @default.
• W2326249637 hasConcept C143998085 @default.
• W2326249637 hasConcept C2776187077 @default.
• W2326249637 hasConcept C2777164284 @default.
• W2326249637 hasConcept C2777176818 @default.
• W2326249637 hasConcept C2778001805 @default.
• W2326249637 hasConcept C2779889926 @default.
• W2326249637 hasConcept C502942594 @default.
• W2326249637 hasConcept C530470458 @default.
• W2326249637 hasConcept C71924100 @default.
• W2326249637 hasConcept C84606932 @default.
• W2326249637 hasConceptScore W2326249637C121608353 @default.
• W2326249637 hasConceptScore W2326249637C126322002 @default.
• W2326249637 hasConceptScore W2326249637C143998085 @default.
• W2326249637 hasConceptScore W2326249637C2776187077 @default.
• W2326249637 hasConceptScore W2326249637C2777164284 @default.
• W2326249637 hasConceptScore W2326249637C2777176818 @default.
• W2326249637 hasConceptScore W2326249637C2778001805 @default.
• W2326249637 hasConceptScore W2326249637C2779889926 @default.
• W2326249637 hasConceptScore W2326249637C502942594 @default.
• W2326249637 hasConceptScore W2326249637C530470458 @default.
• W2326249637 hasConceptScore W2326249637C71924100 @default.
• W2326249637 hasConceptScore W2326249637C84606932 @default.
• W2326249637 hasLocation W23262496371 @default.
• W2326249637 hasOpenAccess W2326249637 @default.
• W2326249637 hasPrimaryLocation W23262496371 @default.
• W2326249637 hasRelatedWork W1994602095 @default.
• W2326249637 hasRelatedWork W2070921366 @default.
• W2326249637 hasRelatedWork W2110224135 @default.
• W2326249637 hasRelatedWork W2114155774 @default.
• W2326249637 hasRelatedWork W2126618397 @default.
• W2326249637 hasRelatedWork W2149506705 @default.
• W2326249637 hasRelatedWork W2151762820 @default.
• W2326249637 hasRelatedWork W2167705375 @default.
• W2326249637 hasRelatedWork W2251738513 @default.
• W2326249637 hasRelatedWork W2321926736 @default.
• W2326249637 hasRelatedWork W2334618704 @default.
• W2326249637 hasRelatedWork W2346240215 @default.
• W2326249637 hasRelatedWork W2431335531 @default.
• W2326249637 hasRelatedWork W2486252778 @default.
• W2326249637 hasRelatedWork W2885510597 @default.
• W2326249637 hasRelatedWork W2886579073 @default.
• W2326249637 hasRelatedWork W3109019480 @default.
• W2326249637 hasRelatedWork W3138099567 @default.
• W2326249637 hasRelatedWork W3201416278 @default.
• W2326249637 hasRelatedWork W2521700049 @default.
• W2326249637 isParatext "false" @default.
• W2326249637 isRetracted "false" @default.
• W2326249637 magId "2326249637" @default.
• W2326249637 workType "article" @default.